20 nov: Ekstraordinær generalforsamling
20 nov: NTR Holding A/S: Delårsrapport for 3. kvartal 2018
20-11-2018 06:51:16

Lundbeck increases its share capital by 6,574 shares (0.0033 % of outstanding shares) as a result of exercise of employee warrants

Valby, Nov. 20, 2018 (GLOBE NEWSWIRE) -- - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 32,870 as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 800 shares at DKK 121 and 5,774 shares at DKK 113. Proceeds to the company are DKK 749,262 (approximately USD 0.114 million). The increase corresponds to approximately 0.0033 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority.

Lundbeck's current share capital amounts to DKK 995,492,110. The capital increase is expected to be finalized shortly, and the total number of voting rights and the total share capital will after this capital increase be:

 

Number of shares (nominal value DKK 5) Nominal value of shares (DKK)    Number of votes 
199,104,996995,524,980199,104,996

Lundbeck contacts

Investors:                                                                                   Media:

Palle Holm Olesen                                                                     Mads Kronborg

Vicedirektør, Investor Relations                                                 Kommunikationschef

palo@lundbeck.com                                                                  mavk@lundbeck.com

+45 30 83 24 26                                                                         +45 36 43 40 00

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Attachment

logo.jpg

Relateret indhold
08 mar - 
Lundbeck henter ny direktør til strategi og forretnings..
05 mar - 
Tirsdagens aktier: Lundbeck og Novozymes i top på nyhed..
19 feb - 
Tirsdagens aktier: William Demant sendt i kulkælderen e..
Relateret debat
21 feb - 
Hej, det går godt med kursen. Så hen mod 26-3 er der ve..
14 feb - 
Synes også der er en høj fejlrate hos Lundbæk. De blive..
14 feb - 
hvornår har de sidst haft succes med deres forskning ?
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Recessionsfrygt i obligationsmarkedet

22-03-2019 15:08:12
Rentemarkederne har i dag sendt flere signaler, som analytikere betegner som klare signaler om lavere vækst og måske endda recession.Således faldt den tyske 10-årige statsobligationsrente i dag under 0 pct., hvilket afspejler investorernes frygt for den europæiske vækst. Tal, der viser indkøbschefernes forventninger til fremtiden, de såkaldte PMI-tal, faldt kraftigere end ventet i marts i flere eu..

Tysk 10-års rente falder under 0 pct. – "Gassen er gået af ballonen"

Relaterede nyheder
22-03-2019 11:26:06
De tyske PMI-tal, som i dag blev i dag offentliggjort, faldt til 44,7 fra 47,6 og rammer dermed laveste niveau siden september 2012. I en kommentar til Euroinvestor udtaler makroanalytiker i Sydbank, Mathias Rømer Sproegel: "Dagens læsning af de tyske PMI’er var ikke rar læsning for investorerne. Bekymringer om Brexit, den globale handelskrig mellem USA og Kina samt fortsat store problemer i den t..

Lars Christensens Verden - Episode 12: Bankernes rolle i samfundet

Relaterede nyheder
22-03-2019 07:12:24
I ”Lars Christensens Verden” går økonom og chefredaktør på Euroinvestor Lars Christensen bag om markedet i samtaler med professionelle markedsaktører, kommentatorer og økonomiske og finansielle forskere. Det handler om, hvad det i virkeligheden er, der driver de finansielle markeder. Det er ikke investeringsråd, men mottoet er, at den, der ved mest, tjener mest. Det leveres alt sammen med humor og..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo udbyttemilliarder kan trække C25 i rødt
2
Middag: Sydbank og Vestas til bunds i rødt marked
3
Vestas/JPMorgan: Sænker anbefaling til "undervægt" - GENT
4
Zealand/Jefferies: Kursmål løftes med små 20 pct. efter partneraftale
5
Recessionsfrygt i obligationsmarkedet

Relaterede aktiekurser

Lundbeck A/S 301.60 -0,2% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. marts 2019 21:18:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190320.1 - EUROWEB5 - 2019-03-22 21:18:59 - 2019-03-22 21:18:59 - 1 - Website: OKAY